The Q4 net loss was less than the Rs 311-crore loss in the same quarter of FY22, but more than the sequential loss of -Rs 102 crore, in the previous quarter

Promoters unpledged 2.60% of shares in last quarter. Total pledge stands at 15.64% of promoter holdings

Wockhardt Ltd.

26 May 2023

1492.80

-1.53%

Wockhardt Consolidated March 2023 Net Sales at Rs 678.00 crore, up 3.51% Y-o-Y

Moneycontrol

Promoters unpledged 2.60% of shares in last quarter. Total pledge stands at 15.64% of promoter holdings

Wockhardt Standalone March 2023 Net Sales at Rs 291.00 crore, down 38.61% Y-o-Y

Moneycontrol | 26 May 2023

Wockhardt Ltd.

26 May 2023

1492.80

-1.53%

to see Rapid results content

Wockhardt Ltd.

22 May 2023

1492.80

-1.53%

Wockhardt, directors settle case with Sebi, pays Rs 76 lakh for settlement

Business Standard

Drug maker Wockhardt and its three directors on Monday settled with Sebi a case pertaining to alleged non-disclosure of adverse observations made by the USFDA about the company's manufacturing facility to the exchanges in 2013. The entities together paid Rs 76.68 lakh towards settlement charges. While Wockhardt paid Rs 36.70 lakh, its three directors -- Habil Khorakiwala, Murtaza Khorakiwala and Huzaifa Khorakiwala -- paid Rs 13.32 lakh each towards the settlement fee to the capital markets regulator, according to a Sebi order. They had proposed to settle the pending proceedings, without admitting or denying the findings of fact and conclusions of law, through a settlement order, as per Sebi. It was alleged that they had violated the Securities Contracts (Regulation) Act (SCRA) and insider trading rules. Khorakiwalas' are also the promoter and promoter group of Wockhardt. In a show cause notice issued in September 2022, Sebi alleged that Wockhardt had failed to enforce the code o

Number of FII/FPI investors increased from 171 to 186 in Jun 2025 qtr.

Wockhardt Ltd.

02 Mar 2023

1492.80

-1.53%

Wockhardt's former official settles insider trading case with Sebi

Business Standard

A former official of drug maker Wockhardt on Thursday settled with Sebi a case pertaining to alleged non-disclosure of adverse observations made by the USFDA about the company's manufacturing facility to the exchanges in 2013. Vijay Khetan, who was the compliance officer of Wockhardt, paid Rs 27.06 lakh towards the settlement charges to the capital markets regulator for the alleged violations of insider trading rules, the Securities and Exchange Board of India (Sebi) said in an order. The order came after Khetan proposed to settle the pending proceedings through a settlement order. Sebi, through a show cause notice in September 2022, alleged that Khetan, being the compliance officer of Wockhardt at the relevant point of the time, had failed to ensure disclosure of price sensitive information immediately to stock exchanges. Therefore, he allegedly violated the code of conduct specified under the insider trading rules, as per the show cause notice. It was also alleged that Wockhardt

Wockhardt Ltd. is trading above its 200 day SMA of 1472.2

Wockhardt Ltd.

26 Feb 2023

1492.80

-1.53%

Wockhardt plans to roll out two vaccines from UK plant in a year

Business Standard

Drug firm Wockhardt plans to roll out two vaccines within a year from its UK-based facility as part of a tie-up with Serum Institute of India, a top company official said. Last year, a Wockhardt unit tied up with a subsidiary of Serum Institute of India to set up a vaccine manufacturing facility in Wrexham, North Wales (UK). "Serum has identified two vaccines and we plan to manufacture these products within the next 12 months after exhibit batches and regulatory approval is received," Wockhardt Managing Director and Global CEO Murtaza Khorakiwala said in an analyst call. Elaborating on the tie-up, he noted that the company has already concluded an agreement with Serum and as a result of that Wockhardt has received 10 million pounds as a contribution for reserving the manufacturing facility for 150 million doses per year of vaccine for 15 years. "This is 150 million doses per year for about a 15-year agreement. And in addition to a contract manufacturing, there is a joint venture ..